OPUS GENETICS INC. -
1.0593
26-November-24 10:07:12
15 minutes delayed
Stocks
-0.0407
-3.70%
Today's range
1.0400 - 1.1143
ISIN
N/A
Source
NASDAQ
-
22 Jul 2021 07:00:02 By Nasdaq GlobeNewswire
-
Ocuphire Selected to Present at Multiple Ophthalmic Conferences in July
13 Jul 2021 08:00:01 By Nasdaq GlobeNewswire
-
Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
09 Jul 2021 16:00:00 By Nasdaq GlobeNewswire
-
Ocuphire’s VEGA-1 Phase 2 Trial in Presbyopia Meets Primary and Secondary Endpoints
30 Jun 2021 06:15:00 By Nasdaq GlobeNewswire
-
Ocuphire Announces Addition to the Russell Microcap® Index
11 Jun 2021 06:30:00 By Nasdaq GlobeNewswire
-
Ocuphire Announces Closing of $15 Million Registered Direct Offering Priced At-the-Market
08 Jun 2021 15:10:00 By Nasdaq GlobeNewswire
-
Ocuphire Announces Appointment of Jay S. Pepose, M.D., Ph.D. to Its Board of Directors
08 Jun 2021 07:00:01 By Nasdaq GlobeNewswire
-
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
04 Jun 2021 08:04:27 By Nasdaq GlobeNewswire
-
20 May 2021 06:30:00 By Nasdaq GlobeNewswire
-
18 May 2021 06:30:00 By Nasdaq GlobeNewswire
-
12 May 2021 06:30:00 By Nasdaq GlobeNewswire
-
Ocuphire Announces Financial Results for the First Quarter 2021 and Provides Corporate Update
07 May 2021 07:00:00 By Nasdaq GlobeNewswire
-
22 Apr 2021 07:00:02 By Nasdaq GlobeNewswire
-
Ocuphire Initiates ZETA-1 Phase 2 Clinical Trial Investigating APX3330 in Diabetic Retinopathy
08 Apr 2021 07:31:26 By Nasdaq GlobeNewswire
-
Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01 Apr 2021 16:10:53 By Nasdaq GlobeNewswire
-
15 Mar 2021 05:00:00 By Nasdaq GlobeNewswire
-
Ocuphire Announces Financial Results for the Full Year 2020 and Provides Corporate Update
10 Mar 2021 15:30:00 By Nasdaq GlobeNewswire
-
05 Mar 2021 07:44:07 By Nasdaq GlobeNewswire
-
Ocuphire to Participate in March Investor Conferences
04 Mar 2021 07:27:09 By Nasdaq GlobeNewswire
-
Ocuphire Initiates Enrollment in VEGA-1 Phase 2 Trial Investigating Nyxol in Presbyopia
18 Feb 2021 07:53:31 By Nasdaq GlobeNewswire